The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs
Abstract
Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless, daily injections can be painful and distressing for some patients, often resulting in non-adherence and reduction of treatment outcomes. This has prompted the development of numerous long-acting GH (LAGH) analogs that allow for decreased injection frequency, ranging from weekly, bi-weekly to monthly. These LAGH analogs are attractive as they may theoretically offer increased patient acceptance, tolerability, and therapeutic flexibility. Conversely, there may also be pitfalls to these LAGH analogs, including an unphysiological GH profile and differing molecular structures that pose potential clinical issues in terms of dose initiation, therapeutic monitoring, incidence and duration of side-effects, and long-term safety. Furthermore, fluctuations of peak and trough serum GH and IGF-I levels and variations in therapeutic efficacy may depend on the technology used to prolong GH action. Previous studies of some LAGH analogs have demonstrated non-inferiority compared to daily rhGH in terms of increased growth velocity and improved body composition in children and adults with GHD, respectively, with no significant unanticipated adverse events. Currently, two LAGH analogs are marketed in Asia, one recently approved in the United States, another previously approved but not marketed in Europe, and several others proceeding through various stages of clinical development. Nevertheless, several practical questions still remain, including possible differences in dose initiation between naïve and switch-over patients, methodology of dose adjustment/s, timing of measuring serum IGF-I levels, safety, durability of efficacy and cost-effectiveness. Long-term surveillance of safety and efficacy of LAGH analogs are needed to answer these important questions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, somapacitan, a reversible albumin-binding GH analog has been approved for adult GHD in the U.S. (August 2020) and Europe (March 2021) and is currently being studied in pediatric populations.109”
In the citing paper
“Additional LAGH options have been approved outside of the U.S. for the treatment of pediatric GHD, including somatrogon (Canada, Australia, Japan, and the European Union), somatropin (South Korea), and PEGylated somatropin (China).108,109,111”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“Early epidemiological studies have demonstrated associations of elevated and high normal serum IGF-I levels with increased risk of cancers (89).”
BackgroundSalomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Ho, K. K. Y., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0631 · Cited by 615
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298 · cited 2×
“More recent consensus guidelines have emphasized the importance of individualized rhGH dosing in the treatment of adults with GHD, with the primary objective of achieving normalization of age-appropriate serum IGF-I levels (38).”
BackgroundResultSelf-citationRhie, Y.-J., Yoo, J.-H., Choi, J.-H., Chae, H.-W., Kim, J. H., Chung, S., Hwang, I. T., Shin, C. H., Kim, E. Y., & Kim, H.-S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216927 · Cited by 49
Hughes, I. P., Choong, C., Rath, S., Atkinson, H., Cotterill, A., Cutfield, W., Hofman, P., & Harris, M. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.04.006 · Cited by 32
Research works printed but not linked: 71
- Allen, 2016, Growth hormone safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults, Eur J Endocrinol, 174, 10.1530/EJE-15-0873 · DOI · Paper page
- Grimberg, 2016, Drug, Therapeutics C, Ethics Committee of the Pediatric Endocrine S. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency, Horm Res Paediatr, 86, 10.1159/000452150 · DOI · Paper page
- Richmond, 2016, Treatment of growth hormone deficiency in children, adolescents and at the transitional age, Best Pract Res Clin Endocrinol Metab, 30, 10.1016/j.beem.2016.11.005 · DOI
- Holdaway, 2015, Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults, Clin Endocrinol (Oxf), 83, 85, 10.1111/cen.12691 · DOI
- Kremidas, 2013, Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers, J Pediatr Nurs, 28, 55, 10.1016/j.pedn.2011.12.006 · doi:10.1016/j.pedn.2011.12.006
- Battelino, 2017, Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial, Clin Endocrinol (Oxf), 87, 10.1111/cen.13409 · DOI
- Chatelain, 2017, A randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency, J Clin Endocrinol Metab, 102, 10.1210/jc.2016-3776 · doi:10.1210/jc.2016-3776
- Cohen-Barak, 2017, Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and Caucasian subjects, Clin Pharmacol Drug Dev, 6, 10.1002/cpdd.294 · DOI
- Cohen-Barak, 2015, Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency, Eur J Endocrinol, 173, 10.1530/EJE-15-0554 · DOI
- Fisher, 2017, Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children, Horm Res Paediatr, 87, 10.1159/000470842 · doi:10.1159/000470842
- Gilfoyle, 2018, A first-in-man phase 1 trial for long-acting TransCon Growth Hormone, Growth Horm IGF Res, 39, 10.1016/j.ghir.2017.12.002 · DOI
- Hou, 2016, Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children, Drug Des Devel Ther, 10, 13, 10.2147/DDDT.S93183 · DOI
- Hoybye, 2017, A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency, Endocr Connect, 6, 10.1530/EC-17-0007 · DOI
- Kramer, 2017, Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and Caucasian adults, Clin Pharmacol Drug Dev, 7, 10.1002/cpdd.414 · DOI
- Luo, 2017, Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies, Eur J Endocrinol, 177, 195, 10.1530/EJE-16-0905 · DOI
- Strasburger, 2017, MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults, Eur J Endocrinol, 176, 10.1530/EJE-16-0748 · DOI
- Thornton, 2019, TransCon growth hormone in the treatment of pediatric growth hormone deficiency: results of the Phase 3 heiGHt trial, J Endocrinol Soc, 3, 10.1210/js.2019-OR17-4 · DOI
- Hoffman, 2005, Genentech Adult Growth Hormone Deficiency Study G. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency, J Clin Endocrinol Metab, 90, 10.1210/jc.2005-0928 · DOI
- Kemp, 2004, Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children, J Clin Endocrinol Metab, 89, 10.1210/jc.2003-030825 · doi:10.1210/jc.2003-030825
- Silverman, 15, A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency, J Pediatr Endocrinol Metab 2002, 2, 10.1515/JPEM.2002.15.S2.715 · DOI
- Moore, 2016, A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency, J Clin Endocrinol Metab, 101, 10.1210/jc.2015-3279 · DOI
- Yuen, 2013, A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults, J Clin Endocrinol Metab, 98, 10.1210/jc.2013-1437 · DOI
- Laursen, 2001, Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults, J Clin Endocrinol Metab, 86, 10.1210/jc.86.3.1222 · DOI
- Burns, 1981, Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone, Eur J Pediatr, 137, 10.1007/BF00441309 · DOI · Paper page
- Kastrup, 1983, Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children, Acta Endocrinol (Copenh), 104, 10.1530/acta.0.1040148 · doi:10.1530/acta.0.1040148
- Collett-Solberg, 2019, Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective, Horm Res Paediatr, 92, 1, 10.1159/000502231 · DOI · Paper page
- Jorgensen, 1989, Beneficial effects of growth hormone treatment in GH-deficient adults, Lancet, 1, 10.1016/S0140-6736(89)92328-3 · DOI · Paper page
- de Boer, 1996, Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.4.8636336 · DOI
- Johannsson, 1997, Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults, Clin Endocrinol (Oxf), 47, 10.1046/j.1365-2265.1997.3271123.x · DOI · Paper page
- Moller, 1993, Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters, Clin Endocrinol (Oxf), 39, 10.1111/j.1365-2265.1993.tb02386.x · DOI
- Cuneo, 1998, The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults, J Clin Endocrinol Metab, 83, 10.1210/jc.83.1.107 · DOI · Paper page
- Burman, 1997, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women, J Clin Endocrinol Metab, 82, 10.1210/jc.82.2.550 · DOI · Paper page
- Johannsson, 1996, The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender, J Clin Endocrinol Metab, 81, 10.1210/jcem.81.4.8636370 · DOI · Paper page
- Christiansen, 2016, Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations, Eur J Endocrinol, 174, 10.1530/EJE-16-0111 · DOI
- Johnson, 1996, A month-long effect from a single injection of microencapsulated human growth hormone, Nat Med, 2, 10.1038/nm0796-795 · DOI · Paper page
- Peter, 2012, Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD), J Clin Endocrinol Metab, 97, 10.1210/jc.2011-2234 · DOI
- Hwang, 2018, Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: a randomized, controlled Phase II study, Horm Res Paediatr, 90, 54, 10.1159/000489262 · doi:10.1159/000489262
- de Schepper, 2011, Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics, Eur, 165, 10.1530/EJE-11-0536 · DOI
- Touraine, 2009, Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH, Eur J Endocrinol, 161, 10.1530/EJE-09-0422 · DOI
- Sprogoe, 2017, The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency, Endocr Connect, 6, 10.1530/EC-17-0203 · DOI
- Design and rationale for the height trial, a phase 3 transcon GH study in children with growth hormone deficiency BeckertM Brian KarpfD MortensenE MardellJ ChristoffersenED LeffJA Orlando, FLEndocrine Reviews. Conference: 99th Annual Meeting of the Endocrine Society, ENDO 2017. United States. Vol 382017
- Thygesen, 2017, Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone, Growth Horm IGF Res, 35, 8, 10.1016/j.ghir.2017.05.006 · doi:10.1016/j.ghir.2017.05.006
- Thygesen, 2016, (NNC0195-0092) a Novel Long Acting Human GH Derivative Binds Tightly, but Reversibly to Albumin in Plasma, i1
- Juul, 2019, Pharmacokinetics and pharmacodynamics of once-weekly Somapacitan in children and adults: supporting dosing rationales with a model-based analysis oftThree phase I trials, Clin Pharmacokinet, 58, 63, 10.1007/s40262-018-0662-5 · DOI
- Savendahl, 2020, Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa614 · doi:10.1210/clinem/dgaa614
- Johannsson, 2018, Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial, Eur J Endocrinol, 178, 10.1530/EJE-17-1073 · DOI
- Otsuka, 2020, Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone, Clin Endocrinol (Oxf), 93, 10.1111/cen.14273 · DOI
- Johannsson, 2020, Once-weekly Somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial, J Clin Endocrinol Metab, 105, 10.1210/clinem/dgaa049 · DOI
- Kim, 2017, Preclinical Pharmacokinetic and Pharmacodynamic Studies of a Novel, Long Acting Growth Hormone (AG-B1512), i1
- Lee, 2016, Human Phase 1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males, Horm Res Paediatr, 86, 1, 10.1159/000449142 · doi:10.1159/000449142
- Wilkinson, 2007, Ross RJ. A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist, Nat Med, 13, 10.1038/nm1610 · doi:10.1038/nm1610
- Kim, 2013, Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane, Nanoscale, 5, 10.1039/c3nr00474k · DOI
- Lee, 2018, A Pharmacokinetic-Pharmacodynamic Analysis Of GX-H9, A Long-acting Hybrid Fc-fused Recombinant Human Growth Hormone (rhGH), i1
- Ku, 2018, Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults, Eur J Endocrinol, 179, 10.1530/EJE-18-0185 · DOI
- Kang, 2015, A Novel Long Acting Growth Hormone (HM10560A) Demonstrated Good Tolerability and Weekly Potential in Healthy Male Subjects after Single Administration, i1
- Kang, 2015, 6 Month Results of a Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long Acting r-Hgh-HMC001 Conjugate in Adult Patients with Growth Hormone Deficiency (AGHD), i1
- Zelinska, 2017, Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children, J Clin Endocrinol Metab, 102, 10.1210/jc.2016-3547 · DOI
- Miller, 2020, Long-acting growth hormone preparations - current status and future considerations, J Clin Endocrinol Metab, 105, dgz149, 10.1210/clinem/dgz149 · DOI
- Lippe, 1979, Use of growth hormone-gel, Arch Dis Child, 54, 10.1136/adc.54.8.609 · doi:10.1136/adc.54.8.609
- Biller, 2013, Twelve-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency, Pituitary, 16, 10.1007/s11102-012-0422-8 · doi:10.1007/s11102-012-0422-8
- Hoybye, 2015, Status of long-acting-growth hormone preparations–2015, Growth Horm IGF Res, 25, 10.1016/j.ghir.2015.07.004 · DOI
- Boguszewski, 2017, Update on GH therapy in adults, F1000Res, 6, 2017, 10.12688/f1000research.12057.1 · DOI
- Maniatis, 2020, Phase 3 fliGHt trial: experience of switching from daily growth hormone therapy to once-weekly TransCon HGH in children with growth hormone deficiency, J Endocrinol Soc, 4, 10.1210/jendso/bvaa046.963 · doi:10.1210/jendso/bvaa046.963
- Deal, 2020, Somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric Phase 3 clinical trial, J Endocrinol Soc, 4, 10.1210/jendso/bvaa046.1279 · doi:10.1210/jendso/bvaa046.1279
- Rasmussen, 2014, A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile, J Clin Endocrinol Metab, 99, 10.1210/jc.2014-1702 · DOI
- Rasmussen, 2016, Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency, J Clin Endocrinol Metab, 101, 10.1210/jc.2015-1991 · DOI
- Boguszewski, 2020, Individual sensitivity to growth hormone replacement in adults, Rev Endocr Metab Disord, 10.1007/s11154-020-09605-1 · DOI
- Ahangari, 2004, Growth hormone antibodies formation in patients treated with recombinant human growth hormone, Int J Immunopathol Pharmacol, 17, 10.1177/039463200401700105 · DOI
- Binder, 2019, Biological Significance of Anti-GH Antibodies in Children Treated with rhGH, Horm Res Paediatr, 91, 17, 10.1159/000497409 · doi:10.1159/000497409
- Hoybye, 2013, Long-acting growth hormone, Paediatr Drugs, 15, 10.1007/s40272-013-0059-8 · DOI
- Johannsson, 2011, Long-acting growth hormone for replacement therapy, J Clin Endocrinol Metab, 96, 10.1210/jc.2011-0689 · DOI
Cited by
Wexler, T. L., Reifschneider, K., Backeljauw, P., Cárdenas, J. F., Hoffman, A. R., Miller, B. S., & Yuen, K. C. J. (2023) · Journal of Neurotrauma · doi:10.1089/neu.2022.0384 · Cited by 19
Self-citationGrowth hormone replacement therapy in childhood-onset craniopharyngioma
van Iersel, L., van Schaik, J., & van Santen, H. M. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.101998 · Cited by 6
Metadata
- Authors
- Yuen, K. C. J., Miller, B. S., Boguszewski, C. L., & Hoffman, A. R.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-24
- Volume
- 12
- ISSN
- 1664-2392
- Cited by
- 63
- References
- 7
- Update notices
- corrigendum (2021-06-28)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. https://app.cochat.ai/papers/10.3389/fendo.2021.637209
- The paper
- Yuen, K. C. J., Miller, B. S., Boguszewski, C. L., & Hoffman, A. R. (2021). Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.637209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.